Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- VYGR
- Price
- 3.17
- Stock movement up
- +0.18 (6.02%)
- Company name
- Voyager Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 173.16M
- Ent value
- 156.37M
- Price/Sales
- 1.06
- Price/Book
- 0.52
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- 6.69
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -64.10%
- 3 year return
- -29.06%
- 5 year return
- -19.24%
- 10 year return
- -
Last updated: 2025-04-12
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
VYGR does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | 6.69 |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | 9.45 |
| EV to EBITDA | 8.53 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 1.06 |
| Price to Book | 0.52 |
| EV to Sales | 0.95 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 54.63M |
| EPS (TTM) | 0.45 |
| FCF per share (TTM) | -0.53 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 163.78M |
| Gross profit (TTM) | 126.80M |
| Operating income (TTM) | 9.07M |
| Net income (TTM) | 25.88M |
| EPS (TTM) | 0.45 |
| EPS (1y forward) | -1.41 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 77.42% |
| Operating margin (TTM) | 5.54% |
| Profit margin (TTM) | 15.80% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 112.53M |
| Net receivables | 15.95M |
| Total current assets | 373.44M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 49.72M |
| Total assets | 426.04M |
| Accounts payable | 3.16M |
| Short/Current long term debt | 45.35M |
| Total current liabilities | 44.21M |
| Total liabilities | 95.73M |
| Shareholder's equity | 330.31M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -26.64M |
| Capital expenditures (TTM) | 4.12M |
| Free cash flow (TTM) | -30.76M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | 7.84% |
| Return on Assets | 6.07% |
| Return on Invested Capital | 7.67% |
| Cash Return on Invested Capital | -9.12% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 2.98 |
| Daily high | 3.19 |
| Daily low | 2.92 |
| Daily Volume | 309K |
| All-time high | 31.31 |
| 1y analyst estimate | 17.10 |
| Beta | 0.89 |
| EPS (TTM) | 0.45 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 12 May 2025 |
Downside potential
Loading...
Downside potential data
| VYGR | S&P500 | |
| Current price drop from All-time high | -89.88% | -12.89% |
| Highest price drop | -92.11% | -56.47% |
| Date of highest drop | 5 Oct 2021 | 9 Mar 2009 |
| Avg drop from high | -64.32% | -11.07% |
| Avg time to new high | 148 days | 12 days |
| Max time to new high | 1787 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
173.16M
Marketcap category
Small-cap
Description
Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
Employees
162
Investor relations
-
SEC filings
CEO
G. Andre Turenne
Country
USA
City
Cambridge
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page